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Background: Tri- and tetra-nucleotide repeats in mammalian genomes can induce formation of alternative non-B
DNA structures such as triplexes and guanine (G)-quadruplexes. These structures can induce mutagenesis,
chromosomal translocations and genomic instability. We wanted to determine if proteins that bind triplex DNA
structures are quantitatively or qualitatively different between colorectal tumor and adjacent normal tissue and if
this binding activity correlates with patient clinical characteristics.
Methods: Extracts from 63 human colorectal tumor and adjacent normal tissues were examined by gel shifts
(EMSA) for triplex DNA-binding proteins, which were correlated with clinicopathological tumor characteristics using
the Mann-Whitney U, Spearman’s rho, Kaplan-Meier and Mantel-Cox log-rank tests. Biotinylated triplex DNA and
streptavidin agarose affinity binding were used to purify triplex-binding proteins in RKO cells. Western blotting and
reverse-phase protein array were used to measure protein expression in tissue extracts.
Results: Increased triplex DNA-binding activity in tumor extracts correlated significantly with lymphatic disease,
metastasis, and reduced overall survival. We identified three multifunctional splicing factors with biotinylated triplex
DNA affinity: U2AF65 in cytoplasmic extracts, and PSF and p54nrb in nuclear extracts. Super-shift EMSA with
anti-U2AF65 antibodies produced a shifted band of the major EMSA H3 complex, identifying U2AF65 as the protein
present in the major EMSA band. U2AF65 expression correlated significantly with EMSA H3 values in all extracts and
was higher in extracts from Stage III/IV vs. Stage I/II colon tumors (p = 0.024). EMSA H3 values and U2AF65
expression also correlated significantly with GSK3 beta, beta-catenin, and NF- B p65 expression, whereas p54nrb
and PSF expression correlated with c-Myc, cyclin D1, and CDK4. EMSA values and expression of all three splicing
factors correlated with ErbB1, mTOR, PTEN, and Stat5. Western blots confirmed that full-length and truncated
beta-catenin expression correlated with U2AF65 expression in tumor extracts.
Conclusions: Increased triplex DNA-binding activity in vitro correlates with lymph node disease, metastasis, and
reduced overall survival in colorectal cancer, and increased U2AF65 expression is associated with total and
truncated beta-catenin expression in high-stage colorectal tumors.* Correspondence: Heike.Allgayer@umm.de
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DNA and RNA are dynamic molecules that adopt
several different secondary and tertiary structures. DNA
can form a stable triple helix in which a purine-
or pyrimidine-rich third strand forms sequence-specific
H-bonds (Hoogsteen and reverse-Hoogsteen) with a
purine-rich strand in the major groove of the Watson-
Crick duplex in polypyrimidine-polypurine repeat
sequences [1]. Guanine (G)-rich DNA and RNA can also
form G-quadruplexes that also use Hoogsteen and re-
verse Hoogsteen G*G bonds in a non-canonical four-
stranded topology. G-quadruplexes specifically have
been implicated at DNA telomere ends, the purine-rich
DNA strands of oncogenic promoters, and in RNA
5’-untranslated regions (UTR) near translation start
sites [2]. For example, a nuclease-sensitive element in
the human c-MYC promoter that can form either a
DNA triplex or G-quadruplex interferes with DNA tran-
scription [3]. Transient Hoogsteen base pairs have been
detected in DNA duplexes bound to transcription fac-
tors and in damaged DNA, suggesting that the DNA
double helix can resonate and form excited-state Hoogs-
teen base pairs that can expand its structural complexity
[4].
Genomic instability in association with carcinogenesis
is well established and promotes multiple hallmarks of
cancer [5]. Repetitive DNA, such as tri- and tetranucleo-
tide sequences, is genetically unstable, and expansions of
such DNA repeats are associated with numerous heredi-
tary neurological diseases including Fragile X syndrome,
myotonic dystrophy, and Friedreich’s ataxia [6,7]. Many
of these DNA repeat sequences can exist in at least two
different conformations, and at least 10 non-B DNA
conformations can form, perhaps transiently, at specific
sequences due to negative supercoiling generated by DNA
replication, transcription, protein binding, or during DNA
repair [8]. Non-B DNA structures such as cruciforms, tri-
plexes and G-quadruplexes can cause mutations such as
deletions, expansions, and translocations [9,10]. Bacolla
et al. found that genes containing long polypyrimidine-
polypurine sequences are more susceptible to chromo-
somal translocations than genes that do not contain these
sequences [11]. Researchers have located “hotspot” regions
of the genome at or near sequences with the potential to
form non-B DNA structures, including the region in the
promoter of the human c-MYC gene capable of forming
triplex or G-quadruplex DNA that overlaps with one of
the major breakpoint hotspots in c-MYC-induced lymph-
omas and leukemias [12,13]. The recently created Non-B
Database (http://nonb.abcc.ncifcrf.gov) can be used to pre-
dict the capability of a DNA sequence in mammalian gen-
omes to form any of a variety of non-B structures [14].
While the existence of triplex or G-quadruplex nucleic
acids in vivo has yet to achieve mainstream acceptance,eukaryotic proteins that recognize and bind to these alter-
native structures do exist. For example, the Fragile X men-
tal retardation protein (FMRP) binds an intramolecular
G-quartet in target mRNAs, and loss of function of this
protein causes the Fragile X mental retardation syndrome
[15]. We have studied proteins in Saccharomyces cerevi-
siae and HeLa carcinoma cells that bind specifically to a
purine-motif triplex DNA probe in gel shifts (EMSA)
where the third strand is G-rich and photo-crosslinked
with a psoralen group (Ps~) [16-18]. Stm1, the major
purine-motif triplex DNA-binding protein in S. cerevisiae,
also binds to G-quartet DNA and RNA in vitro [19]. Using
Southwestern blotting where HeLa nuclear extracts were
separated by SDS-PAGE, blotted and probed with the
same radio-labeled purine triplex DNA used in EMSA, we
found that 100-, 60-, and 15-kDa bands were hybridized
with the triplex DNA probe, whereas only the 100-kDa
band was also hybridized with the parent duplex DNA
probe [16]. RecQ-family helicases, including the WRN
helicase, have been shown to preferentially bind to and
unwind aberrant DNA structures such as triplex and
G-quadruplex DNAs, which are believed to exist in vivo as
intermediates in DNA replication, recombination, and
repair. The WRN helicase is deficient in patients with
Werner syndrome, an autosomal recessive disease causing
premature aging that is associated with numerous age-
related phenotypes, including a high predisposition to can-
cer [20]. Others have examined specific aspects of WRN
expression in colorectal cancer, such as the presence of
allelic variants and colorectal cancer risk and WRN pro-
moter methylation as it correlates with a CpG island
methylation phenotype (CIMP)-high diagnosis [21,22].
These studies led us to question whether triplex DNA-
binding proteins and WRN helicase expression are quanti-
tatively and/or qualitatively different in human colorectal
tumors and corresponding normal tissues, if there is any
correlation with clinical prognosis, and identify purine-
motif triplex DNA-binding proteins in human cells.
Numerous genetic, cytogenetic, and epigenetic aberra-
tions act at specific stages in colorectal cancer initiation and
progression and influence response to therapy, such as
inactivation of tumor suppressor APC as an initiating event
and KRAS or BRAF mutations as markers of non-response
to EGFR-targeted therapy [23]. High-throughput studies
have suggested the existence of additional undiscovered
cancer genes that may promote colorectal cancer develop-
ment [24-26]. Colorectal cancer is also one of the more
genetically unstable cancers, with about 65% of sporadic
adenomas and cancers being characterized by chromosomal
instability (CIN), 10-15% characterized by microsatellite in-
stability (MSI), and approximately 20% having a CIMP
phenotype, with some overlap among these characteristics.
We have found higher triplex DNA-binding activity
in vitro in colorectal tumor extracts than in corresponding
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binding activity correlated significantly with the spread of
cancer to the lymph nodes, metastasis, and reduced overall
survival. We also found that expression of the triplex/
G-quadruplex-unwinding helicase WRN correlated signifi-
cantly with total triplex DNA-binding activity in EMSAs in
both normal and tumor tissue extracts. Biotin purine-motif
triplex DNA affinity identified three multifunctional spli-
cing factors: U2AF65, PSF, and p54nrb, and an anti-
U2AF65 antibody produced a super-shifted EMSA band.
High U2AF65 expression was associated with advanced
colon tumor stages and with p54nrb and PSF expression in
tumors. U2AF65 expression also correlated significantly
with both total and truncated beta-catenin, as well as
NF- B p65, PCNA, EGFR, mTOR, PTEN, and Stat5 in
colorectal tumors.
Materials and methods
Preparation of cytoplasmic and nuclear extracts of tis-
sue and cell lines. Tissue samples of tumor and adjacent
normal mucosa were collected after surgical resections
after informed consent, verification by a pathologist,
and snap-frozen in liquid nitrogen. The patients had not
previously received any chemotherapy, therefore the tis-
sues are chemotherapy naïve. Frozen tissue samples
were prepared as described by Asangani et al. [27]. The
samples were pulverized with a Sartorius Mikrodismem-
brator, then extracted for 30 min on ice with Schaffner
lysis buffer A (10 mM HEPES-Na + pH 7.9, 10 mM KCl,
0.1 mM EDTA pH 8.0, 0.1 mM EGTA pH 8, 1 mM
dithiothreitol, 0.5% Triton X-100, Sigma phosphatase
inhibitor cocktail 2, and Roche Complete Mini protease
inhibitor) and centrifuged at 13,000 rpm, 4°C in a
microcentrifuge to produce cytoplasmic extracts. The
nuclear pellet was extracted for 30 min on ice with
Schaffner buffer C (20 mM HEPES-Na + pH 7.9, 0.4 M
NaCl, 0.1 mM EDTA pH 8.0, 0.1 mM EGTA pH 8.0,
1 mM dithiothreitol, 20% glycerol, with phosphatase
and protease inhibitors) and centrifuged at 13,000 rpm,
4°C in a microcentrifuge to produce nuclear extracts
[28]. Total protein concentrations were determined
using the Pierce BCA Protein Assay kit. Colorectal can-
cer cell lines and HeLa cytoplasmic or nuclear extracts
were similarly prepared using Schaffner buffers A and
C, respectively.
Purine-motif triplex DNA formation and 33P-labeling
Purine triplex DNA oligonucleotide sequences and probe
formation were as previously described [16,17]. The parent
duplex oligonucleotides are PuGA: 5’ – AATTCCTAAGG
GAGGGGAGGGGAGGGTAGCT – 3’ and complementary
strand PuCT: 5’ – AGCTACCCTCCCCTCCCCTCCCT
TAGG – 3’. The parent duplex DNA was made by anneal-
ing equimolar (0.1 mM) concentrations of the PuGA andPuCT oligonucleotides at room temperature after boiling
for 2 min in 40 mM Tris-HCl pH 8.0, 10 mMMgCl2, 0.01%
NP-40. The purine-motif triplex-forming oligonucleotide
(TFO) contained a 4’-(hydroxymethyl)-4,5’,8-trimethylpsora-
len-hexyl (Ps~) moiety at the 5’-terminus (Eurogentec):
5’ – Ps~GGG TGG GGT GGG GTG GGT -3’. To form
triplex DNA, the parent duplex DNA and a 10-fold molar
excess of TFO were incubated for 4 h at 30°C in 40 mM
Tris HCl pH 8.0, 100 mM MgCl2, 0.01% NP-40. Psorale-
nated TFO was then cross-inked with the parent DNA du-
plex with a 366 nm UV transilluminator for 10 min on ice.
Purine triplex DNA (1 x 10-7 M) was 3’ end-labeled with T4
kinase (New England Biolabs) and γ-33P dATP for 1 h at 37°
C. Unincorporated labeling dATP was removed from the
reaction by centrifuging the reaction mixture with an equal
volume of 10 mM Tris-HCl pH 8.0, 10 mM MgCl2,
0.05% Triton X-100 through a G25 Microspin column
(GE Healthcare).
Electrophoretic mobility shift assay (EMSA)
and super-shift EMSA
Gel shifts were also done as previously described
[16,17]. In this study 5 μg total protein from tissue
extracts or 1.5 μg HeLa or colorectal cancer cell line
cytoplasmic or nuclear extracts were mixed with 1 nM
33P-labeled purine triplex DNA and 2 μg poly (dIdC)
carrier DNA in binding buffer (25 mM HEPES-Na + pH
7.9, 50 mM KCl, 10% glycerol, 0.5 mM dithiothreitol,
2 mM MgCl2) for 30 min at room temperature. Protein-
triplex DNA probe complexes were resolved by nonde-
naturing PAGE at 7 V/cm for 90 min through a 5%
acrylamide/0.25% bisacrylamide gel containing 22 mM
Tris borate, 0.5 mM EDTA, and 5% glycerol. Protein-
probe complexes were visualized using autoradiography
and quantitated with a Storm 840 PhosphorImager
(Molecular Dynamics). Major EMSA H3 bands from
each tissue sample were normalized by dividing by the
H3 band value of HeLa nuclear extract present in each
gel. For super-shift EMSA, protein extracts were incu-
bated in the same binding buffer with purine triplex
DNA probe for 30 min at room temperature, then
400 ng of anti-U2AF65 MC3 antibody or mouse IgG
antibody as a negative control (Santa Cruz) were added
to the reaction and incubated for 1 h at room
temperature. PAGE gels were run as for regular EMSA
with the addition of a circulating cooling water bath to
the gel apparatus.
Statistical correlations
The Wilcoxon Sign Rank Test was used to compare the
level of the major EMSA H3 complex and WRN
expression in total, cytoplasmic, and nuclear extracts of
colorectal tumors and corresponding normal tissues.
The Mann-Whitney U test was used with SPSS version
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groups. Spearman correlations among continuous vari-
ables were computed. Chi square (Bonferroni-corrected)
were used for grouped/dichotomized variables. Survival
was estimated using Kaplan-Meier analysis, and differ-
ences were calculated using Mantel-Cox log-rank statis-
tics; primary endpoints were tumor-related death (disease-
specific survival), death (overall survival), and tumor re-
currence (recurrence-free survival, R0-patients only). The
following variables were dichotomized according to the
median value: protein levels in nuclear and total extracts
(cytoplasm and nucleus) ratios (tumor/normal) as high
levels in tumor (values above the median) vs. low levels in
tumor (values below the median) as compared with nor-
mal tissue, involved lymph nodes as pN0 vs. pN1-3,
distant metastasis as M0 vs. M1, surgical curability as
curative vs. non-curative resection (R0 vs. R1/2).
Purification of triplex DNA-binding proteins using biotin/
streptavidin affinity
Biotinylated purine triplex DNA was formed using a 3’ bio-
tinylated PuCT oligonucleotide (Eurogentec): 5’ – AGC
TACCCTCCCCTCCCCTCCCTTAGGAATTTT-biotin-
3’ annealed to the PuGA complementary strand, then
annealed and crosslinked with the Ps ~TFO as described
above. Purification of DNA-binding proteins using bio-
tin/streptavidin affinity systems, as described in Current
Protocols in Molecular Biology [29], was performed in
separate 2 ml reactions containing either 800 μg RKO
colorectal cancer cell nuclear extract or 1085 μg RKO
cytoplasmic extract, EMSA binding buffer (25 mM
HEPES-Na + pH 7.9, 50 mM KCl, 10% glycerol, 0.5 mM
dithiothreitol, 2 mM MgCl2), 600 μg poly (dIdC), 1 nM
biotinylated purine triplex DNA, and 150 μl pretreated
streptavidin agarose (Fluka) while rotating for 2 hr at
room temperature. Streptavidin agarose was gently pel-
leted and washed three times with binding buffer.
Laemmli buffer was added directly to the agarose pellet
and boiled for 5 min to elute bound protein(s). Proteins
were separated using 10% SDS-PAGE and stained with
Coomassie blue. Two bands (100 and 60 kDa) from the
nuclear extract reaction and one band (65 kDa) from the
cytoplasmic extract reaction were excised from the gel
and submitted to the German Cancer Research Center
(DKFZ) Functional Proteome Analysis laboratory for
sequencing and analysis using nano-HPLC ESI-MS-MS
and identified using MASCOT database searches.
Western blotting
Western blot analysis was performed using standard
procedures as described in Current Protocols in Molecu-
lar Biology [27]. 25 μg total protein from tissue or cell
line cytoplasmic or nuclear extract was separated by 10%
SDS-PAGE, then electro-transferred to nitrocellulosemembranes in 25 mM Tris, 190 mM glycine with 20%
methanol. After blocking in 5% milk in Tris-buffered sa-
line with 0.2% Tween-20 (TBST) for 1 hr at room
temperature, membranes were incubated with antibodies
against WRN (H-300 Santa Cruz sc-5629, 1:500),
U2AF65 (MC3 Santa Cruz sc-53942, 1:2000), PSF (39-1
Santa Cruz sc-101137, 1:2000), p54nrb (H-85 Santa
Cruz sc-67016, 1:2000) in 5% milk-TBST for 1 hr at
room temperature, or beta-catenin (L87A12 Cell
Signaling CS-2698, 1:1000) or actin (Sigma A2066,
1:1000) in 5% milk in TBST overnight at 4°C. Blots were
washed with TBST, incubated with the appropriate HRP-
conjugated secondary antibody at 1:4500, and detected by
enhanced chemiluminescence (Pierce, Thermo Scientific)
and autoradiography. Protein bands were quantitated by
densitometry using NIH Image J software and normalized
to actin.
Reverse phase protein array (RPPA)
RPPA was performed as described by Mannsperger et al.
[30]. 2.7 ng cytoplasm or 2.8 ng nuclear protein extract
per spot was printed with a non-contact spotter onto
nitrocellulose slides (Oncyte Avid, Grace Bio-labs, Bend
OR) using an Aushon 2470 Microarrayer (Billerica,
MA). Slides were mounted in a customized incubation
chamber (Metecon, Mannheim Germany), blocked for
1 hr at room temperature with 50% (v/v) Odyssey block-
ing buffer in PBS and individually stained with 37 vali-
dated primary antibodies at 1:300 in blocking buffer at
4°C overnight and Alexa 680-labeled secondary anti-
bodies (Invitrogen) at 1:8000 in PBS with 0.05% Tween
for 1 hr at room temperature. Slides were scanned with
the Licor Odyssey system and spot intensities were cal-
culated with GenePix Pro 5.0 microarray analysis soft-
ware (Molecular Devices). To estimate the total protein
concentration per spot, a slide from each run was
stained with Fast Green FCF (Sigma-Aldrich) as
described by Loebke et al. [31]. Data analysis was done
using R with the RPPanalyzer package from CRAN
(http://cran.r-project.org, [32]). For each antibody the
logged mean of the raw foreground pixel intensities of a
single spot was subtracted by the corresponding logged
Fast Green FCF signal to normalize for the total protein
per spot.
Results
Colorectal tumors have higher triplex DNA-binding
activity than corresponding normal tissue
A summary of clinical characteristics of the 63 study
patients are shown in Table 1. To examine purine-motif
triplex DNA-binding proteins, cytoplasmic and nuclear
extracts from 63 colorectal cancer patients’ tumor and cor-
responding normal tissues were isolated and examined by
gel shifts (EMSA). Figure 1 presents examples of EMSAs
Table 1 Patient clinical characteristics
Tumor characteristics Absolute (n = 63) Relative (%)
Sex Male 46 73%
Female 17 27%
Localization Colon 36 57.1%
Rectum 27 42.9%




Lymph Node Status pN0 37 58.7%
pN1 16 25.4%
pN2 10 15.9%
Metastasis Staging M0 42 66.7%
M1 21 33.3%
Status alive 43 68.1%
dead 20 31.7%
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where in most samples one major band (H3) is present in
varying amounts. In some patients, tumor cytoplasmic
extracts contained a higher amount of the major H3 com-
plex than normal or tumor nuclear extracts (patients 1 and
5), while in other patients, tumor nuclear extracts con-
tained a higher amount of the major H3 complex (patients
6 and 8). Cytoplasmic and nuclear extracts from HeLa cells
were included as positive controls. Normalized EMSA H3
values are listed below each sample. To verify that the
major EMSA H3 band is specific for the triplex DNA
probe, the 33P-labeled parent duplex DNA probe lacking
G*G base pairs did not produce the major H3 complex in
patient tissue or HeLa nuclear extracts (Additional file 1:
Figure S1). EMSA H3 binding values were generally higher
in tumor than normal tissue, whether evaluating cytoplas-
mic extracts (mean=0.512, median=0.509 for tumor tis-
sue; mean=0.386, median=0.384 for normal tissue) or
nuclear extracts (mean=0.361, median=0.368 for tumor
tissue; mean=0.264, median=0.228 for normal tissue) as
shown in Figure 2. Wilcoxon sign rank test results showed
significantly higher triplex DNA EMSA binding activity in
tumor than normal extracts when examining total mea-
sures (p=0.001), cytoplasmic extracts only (p=0.001) and
nuclear extracts only (p=0.012)(Additional file 2). We also
performed EMSA analysis of cytoplasmic and nuclear
extracts of eight colorectal cancer cell lines (GEO, SW480,
HT29, HCT116, Colo206F, wiDR, Colo320, and RKO) and
found that all eight cell lines had a triplex DNA-binding
protein pattern that was very similar to HeLa extracts, with
a moderate amount of the major H3 band produced by
cytoplasmic extracts and an abundant amount of the H3
band produced by nuclear extracts (Additional file 1: Figure
S2a).Increased triplex DNA-binding activity in colorectal
tumors correlates with lymph node disease, metastasis,
and overall survival
We wanted to investigate whether the amount of the
EMSA H3 complex correlated with patient clinicopatholo-
gical data and overall survival. Median follow-up time for
patient clinical data was 28.9 months. Normalized EMSA
data of patient samples were correlated with clinical risk
factors and computed for univariate prognostic impact. We
observed that lymph node disease (N-Stage) was signifi-
cantly associated with the ratio of tumor/normal (T/N)
triplex-binding activity for cytoplasmic and nuclear extracts
and total values (p=0.026; 0.019; 0.017, respectively,
Table 2a). This meant that all patients without lymph node
disease at diagnosis had significantly decreased binding
ratios (T/N) in both cytoplasmic and nuclear extracts. Also,
the triplex DNA-binding activity in tumor nuclear extracts
and total tumor extracts correlated significantly with me-
tastasis (p= 0.031, p=0.046, respectively, Table 2b). Kaplan-
Meier survival analysis using a median cut-off of 1.5
(rounded-up) for the nuclear binding activity ratio (T/N)
showed significantly lower overall survival in patients
whose T/N nuclear binding activity ratio was greater than
1.5 (n=30; p=0.026) than in patients whose ratio was less
than 1.5 (n=33, Figure 3, Additional file 2). This suggested
that although triplex DNA-binding protein(s) were present
in normal colorectal tissue extracts, they were more abun-
dant in tumor extracts. It also suggested that an abundance
of the major triplex-binding EMSA complex (H3) in the
nuclei of tumor cells was associated with metastasis and
reduced overall survival (Additional file 3).Identification of U2AF65 as the protein present
in the EMSA H3 complex
We wished to identify the protein(s) responsible for binding
the triplex DNA probe in the major EMSA H3 complex.
We isolated biotinylated purine-motif triplex DNA-protein
complexes from RKO cells with streptavidin-conjugated
agarose, separated the complexes by SDS-PAGE, and
stained with Coomassie Blue. Protein bands were ana-
lyzed by nano-HPLC ESI-MS-MS and identified using
MASCOT database searches. We identified (1) 100-kDa
and (2) 60-kDa proteins from nuclear extracts and a (3)
65-kDa protein from cytoplasmic extracts. These corre-
sponded to the following proteins:(1) PSF (polypyrimidine tract binding-associated
splicing factor, or SFPQ) [NCBI Protein AAH04534]
(2) P54nrb (nuclear RNA-binding protein) or NonO
[NCBI Protein NP_031389]
(3) U2AF65 (U2 small nuclear RNA auxiliary factor 2
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Figure 1 Electrophoretic Mobility Shift Assay (EMSA) of Resected Tissue Extracts with Purine Triplex DNA. 33P-labeled purine-motif triplex
DNA (1 nM) was complexed with 5 μg total protein from normal cytoplasmic (N cy), normal nuclear (N nu), tumor cytoplasmic (T cy) or tumor
nuclear (T nu) extracts of tissues obtained from eight selected colorectal cancer patients. 1.25 μg HeLa cytoplasmic and nuclear extracts were
used as positive (+) controls. The major EMSA band was H3, indicated with an arrow. Normalized EMSA H3 values are listed below the
corresponding samples. The purine-motif triplex probe alone is shown in lane 1.
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ase II-associated splicing factors, bind as heterodimers, and
are implicated in the regulation of expression of the Myc
family of oncoproteins, COX2, etc. They also bind to and
stimulate topoisomerase I and promote homologous DNApairing and the incorporation of a single-stranded oligo-
nucleotide into homologous superhelical double-stranded
DNA D-loop formation [33,34]. U2AF65, identified from
cytoplasmic extracts, is also an RNA polymerase II-
associated splicing factor that can associate with mRNAs


















Figure 2 Normalized EMSA H3 values for all 63 colorectal cancer patient extracts. Box plots indicating the median normalized EMSA H3
values (white lines in the boxes), upper and lower quartiles (25th through 75th percentiles defined by the shaded box), and ranges of data values
for each extract type. N cyto, cytoplasmic normal tissue extracts; N nuc, nuclear normal tissue extracts; T cyto, cytoplasmic tumor tissue extracts;
Tnuc, nuclear tumor tissue extracts.
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cell cycle regulators, and shuttle continuously between the
nucleus and cytoplasm [35,36].
Super-shift EMSA with a well-characterized monoclonal
antibody against U2AF65 [37] consistently produced aTable 2 Correlation of the ratio of tumor (T) to normal (N) (T/
test statistics (a) by presence of disease in lymph nodes (N-St
(distant metastasis)






Asymp. Sig (2-tailed) 0.026





Asymp. Sig (2-tailed) 0.091super-shifted H3 band in all human extracts tested that
were known to express U2AF65 by Western blot analysis
(RKO and tumor tissue cytoplasmic and nuclear extracts
are shown in Figure 4). This confirmed that U2AF65 is
present in the H3 triplex DNA-protein complex observedN) EMSA H3 values for each patient with clinical features:
age) and (b) by presence of metastasis in distant organs
chotomized






































Figure 3 Overall Survival according to the tumor:normal (T/N) colorectal tissue nuclear triplex DNA-binding activity ratio. Cut-off = 1.5
(rounded-up median).
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p54nrb did not produce any super-shifted bands in our
EMSA analysis (Additional file 1: Figure S3).
U2AF65 expression correlates with EMSA H3 values
and p54nrb and PSF expression in tumor tissues
and with a higher tumor stage
We measured expression of the three splicing factors in
normal and tumor colorectal tissue extracts obtainedRKO cyto RKO nuc
- U2       Ig        - U2        Ig        
1         2         3         4       5         6         7  
Figure 4 Production of a super-shifted H3 band in RKO and patient ti
against U2AF65. 33P-labeled triplex DNA (1 nM) was complexed with 1.5 μ
5-7), 5 μg tumor cytoplasm (T cyto lanes 8-10) or tumor nuclear (T nuc lan
12, 400 ng anti-U2AF65 antibody MC3; lanes 4, 7, and 10, mouse IgG antib
carrier DNA. Lane 1, triplex DNA probe alone.from 51 of the 63 patients using Western blotting to
determine if triplex DNA-binding activity in EMSA
correlates directly with U2AF65, PSF, and/or p54nrb
total protein expression. Spearman correlations indi-
cated that U2AF65 expression correlated significantly
with EMSA H3 values, and that the correlation was
highly significant in tumor extracts (cytoplasmic
p= 1.8e-8; nuclear p = 5.9e-5; total p = 1.8e-8; Table 3a,
Additional file 4). In comparison, PSF and p54nrb werePatient T cyto Patient T nuc
- U2       Ig         - U2                antibody  
H3
H3 supershift
8        9         10       11       12
ssue extracts by super-shift EMSA with a monoclonal antibody
g total protein from RKO cytoplasmic (lanes 2-4), RKO nuclear (lanes
es 11-12) extracts. Lanes 2, 5, 8, and 11, no antibody; lanes 3, 6, 9, and
ody (negative control). Each reaction also contained 2 μg poly (dI-dC)
Table 3 (a) Spearman correlation p values of EMSA H3 values with expression of triplex DNA-binding proteins (3BP)
and (b) correlations of U2AF65 expression to PSF and p54nrb expression in normal and tumor tissue extracts
3BP expression correlated U2AF65 p54nrb PSF
With EMSA H3
Normal cytoplasm 0.0028 0.91 0.66
Normal nucleus 0.015 0.11 0.075
Normal total 0.016 0.26 0.095
Tumor cytoplasm 1.8e-08 0.53 0.019
Tumor nucleus 5.9e-05 0.0071 0.036
Tumor total 1.8e-08 0.0048 7.5e-05
Correlation to U2AF65 p54nrb PSF
Normal cytoplasm 0.00066 0.085
Normal nucleus 0.00037 0.073
Normal total 0.00040 0.094
Tumor cytoplasm 0.0041 0.0002
Tumor nucleus 1e-06 0.0005
Tumor total 1e-06 1e-06
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in cytoplasmic extracts, and their expression correlated
with EMSA H3 values only in tumor nuclear extracts
(p= 0.036 and 0.0071, respectively) (Table 3a). When cor-
relating the expressions of the three splicing factors with
each other, PSF and p54nrb were highly significantly asso-
ciated in nuclear extracts of both normal and tumor tissue
(p= 1e-6 in both) as expected, as they are known to bind
and function as heterodimers. Also, U2AF65 expression
was highly significantly correlated with p54nrb expression
in both normal and tumor nuclear extracts (p= 0.00037
and 1e-6, respectively)(Table 3b), but with PSF expression
only in tumor nuclear extracts (p= 0.0005), suggesting a
unique functional aspect of U2AF65 and PSF in tumor cell
nuclei. We also examined expression of the three splicing
factors identified by biotin triplex DNA affinity in the
eight colorectal cancer cell lines using Western blotting.
Consistent with patient tissue data, U2AF65 expression
from all cell line extracts most closely matched the
abundance of the EMSA H3 band, with moderate
expression in all cytoplasmic extracts and abundant ex-
pression in all nuclear extracts (Additional file 1:
Figure S2b).
Having shown that the EMSA H3 complex was
increased in tumor compared to adjacent normal tissue,
we wished to determine if U2AF65, p54nrb and PSF ex-
pression was associated with tumor stage. U2AF65 pro-
tein expression according to extract type and tumor
stage in all colon tumors is shown in Figure 5. Colon
tumors in Figure 5 in advanced clinical stages, UICC
Stage III and IV (Dukes C and D) express significantly
higher U2AF65 in the cytoplasm and overall than did
tumors at early stages (mean value of U2AF65 tumor
cytoplasm UICC Stage I and II expression = 0.349 vs.UICC Stage III and IV = 0.491; p = 0.024 [Mann-Whitney
U-Test, Additional file 5]). PSF and p54nrb expression
were not significantly correlated with tumor stage. While
both p54nrb and PSF expression were significantly cor-
related with EMSA H3 values in tumor but not normal
tissue extracts, the antibodies against these proteins that
we tested were unable to produce a super-shifted EMSA
band. Thus the relevance of p54nrb and PSF as triplex
DNA-binding proteins remains to be determined.
Expression of the WRN helicase correlates with EMSA H3
binding activity
We wanted to test the hypothesis that proteins that bind to
or stabilize triplexes and G-quadruplexes can act in a yin-
yang fashion (in complementary opposition) with proteins
such as helicases that unwind or destabilize these struc-
tures, and that expression and/or function of these binding
and unwinding proteins may be imbalanced in tumors that
could contribute to genomic instability. We tested 51 pa-
tient colorectal tumor and normal tissue extracts for ex-
pression of the RecQ-family helicase WRN because it is
known to act preferentially on aberrant structures such as
triplexes and G-quadruplexes and to promote genomic in-
tegrity [19]. We used the Wilcoxon sign rank test to deter-
mine if WRN is differentially expressed in normal and
tumor tissue extracts and Spearman’s rho to correlate
WRN helicase expression in normal and tumor tissue
extracts with EMSA H3 data. We detected no significant
differences in normalized WRN expression between normal
and tumor extracts or according to tumor stage (mean
cytoplasmic expression in tumor tissue=0.424, in normal
tissue=0.283; mean nuclear expression in tumor tissue-
=0.275, in normal tissue=0.196; total expression mean in
tumor tissue=0.679, in normal tissue=0.465). However, we
Colon normal cyto Colon normal nuc
Colon tumor cyto Colon tumor nuc
Figure 5 U2AF65 protein expression by colon tumor stage. Total protein (25 μg) from cytoplasmic (cyto) and nuclear (nuc) colon tumor and
normal tissue extracts were separated using 10% SDS-PAGE and electro-transferred to nitrocellulose membranes. Blots were incubated with
anti-U2AF65 antibody MC-3 and detected using chemiluminescence and autoradiography. Blots were reprobed with an anti-actin antibody, and
densitometry was performed using NIH Image J software. U2AF65 expression values were normalized by dividing the actin expression values in
each extract, and plotted according to colon tumor stage using the R program (Additional file 6).
Nelson et al. Molecular Cancer 2012, 11:38 Page 10 of 17
http://www.molecular-cancer.com/content/11/1/38did observe that total WRN expression correlated signifi-
cantly with total EMSA H3 binding values in both normal
tissue (rho 0.296, p=0.03) and tumor extracts (rho 0.460,
p <0.001).
Reverse-phase protein array and western blot analysis
of tissue extracts show a correlation of U2AF65 expression
with total and truncated beta-catenin expression
Another goal of our study was to measure the expression
of numerous cancer-relevant proteins in patient tissue
extracts and correlate it with EMSA H3 values and expres-
sion of the three splicing factors identified using biotin
triplex DNA affinity as a screen to identify potentially rele-
vant functional relationships among these splicing factors
and other well-characterized proteins. Using reverse-phase
protein array (RPPA) analysis, we examined extracts from
51 patients (because not all extracts met the minimum
concentration needed for accurate measurement) for ex-
pression of cancer-related proteins with 37 previously vali-
dated antibodies. Spearman correlation of the expression of
multiple signaling proteins was calculated. Significant cor-
relations after Bonferroni correction for multiple testing
were found with both EMSA H3 values and U2AF65
expression, including NF- B p65, GSK3 beta, beta-catenin,Src, and PI3K p110 alpha (Table 4; exact p values are
shown in Additional file 7: Table S1). The expression levels
of a distinct set of proteins were found to correlate signifi-
cantly with both p54nrb and PSF expression, such as cyclin
D1, c-Myc, JNK1, CDK4, Akt1, and Stat3. Expression of all
three splicing factors and EMSA H3 values also signifi-
cantly correlated with another set of proteins including p38
alpha, ErbB1 (EGFR), mTOR, PTEN, and Stat5.
The most highly significant correlation in our RPPA
analysis was that between U2AF65 expression and beta-
catenin (p = 9e-10), known to be deregulated and a
major player in the etiology of colorectal cancer. To con-
firm our RPPA results, we compared Western blots of
beta-catenin and U2AF65 expression in tissue extracts
from 50 patients. Representative Western blots for six
patients are shown in Figure 6, which includes some pa-
tient samples also shown in Figure 1 EMSAs. These data
were quantitated by densitometry and graphed in
Additional file 1: Figure S4. According to Spearman’s
rho, we observed that total beta-catenin and U2AF65
expression are highly significantly correlated in cytoplas-
mic and nuclear tumor extracts (p = 5.7e-6 and p = 3.1e-
6, respectively), while their expression correlated signifi-
cantly in normal nuclear extracts (p = 0.0018), and
Table 4 Spearman correlations of EMSA H3 values and
triplex DNA-binding protein expression to other proteins
by reverse phase protein array (RPPA)
EMSAH3 U2AF65 p54nrb PSF
Ph-Erk **
NF-κB p65 *** ***








p 38 α ** ** *** ***
Cdk4 ** ***
Akt1 ** ***
ErbB1 *** *** ** ***
Bcl-2 **
mTor *** *** *** ***
P13K p110 α ** ***
PLC γ ***
PTEN *** *** *** ***
Stat3 * ** ***
Stat5 *** *** *** ***
*p< 0.05; **p < 0.01; ***p < 0.001.
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extracts (p = 0.15). In addition, beta-catenin expression
was higher in cytoplasmic and nuclear extracts of stage
III and IV colon tumors than in those of stage I and II
colon tumors (Additional file 1: Figure S5). Western
blots of beta-catenin expression showed truncated bands
(65-80- kDa) for some extracts but not for others, which
was consistent with previous reports of truncated or
novel spliceforms of beta-catenin mRNA [38,39] and an
80-kDa truncated beta-catenin protein [40] in colorectal
cancer. In addition to a significant correlation bet-
ween full-length beta-catenin (92-kDa) expression and
U2AF65 expression, we found a significant correlation
between truncated beta-catenin and U2AF65 expression,
particularly in the cytoplasm (p = 0.0047) and nuclei
(p = 0.022) of tumor cells.
Discussion
The data provides support to the hypothesis that the
major triplex DNA-binding protein in human cells is
more abundant and has higher binding activity in vitro
in extracts from colorectal cancer tissues compared to
adjacent normal tissues. This increased binding activitycorrelated significantly with the expression of triplex/
G-quadruplex DNA-unwinding helicase WRN, and with
the spread of cancer to the lymph nodes, metastasis, and
reduced overall survival. The major triplex DNA-binding
protein in gel shifts was identified as the U2AF65 spli-
cing factor. U2AF65 expression was higher in more
advanced colon tumor stages and correlated significantly
with total and truncated beta-catenin expression.
U2AF is a non-small nuclear ribonucleoprotein (snRNP)
splicing factor required for the binding of U2 snRNP to
the pre-mRNA branch site [41,42]. Purified U2AF is com-
prised of two polypeptides of 65- (U2AF65) and 35-kDa
(U2AF35), respectively. U2AF65 binds to the polypyrimi-
dine (Py) tract adjacent to the 3’ splice site using RNA-
recognition motifs and cross-links to the branch point in
an ATP-independent manner at the earliest stage of spli-
ceosome formation [43]. Both subunits of U2AF are essen-
tial for the viability of many model organisms, such as
zebra fish, Drosophila, C. elegans, and S. pombe [44]. Both
U2AF65 and U2AF35 shuttle continuously between the
nucleus and cytoplasm by a mechanism that involves car-
rier receptors and is independent from binding to mRNA.
It has also been suggested that U2AF participates in the
nuclear export of mRNA [45].
U2AF65 binds to single-stranded RNA and recognizes
a wide variety of pyrimidine (Py)-tracts. The Py-tracts of
higher eukaryotic pre-mRNAs are often interrupted with
purines, yet U2AF65 must identify these degenerate Py-
tracts for accurate pre-mRNA splicing. Based on in vitro
studies, investigators have proposed that U2AF35 assists
U2AF65 recruitment to nonconsensus polypyrimidine
tracts. Pacheco et al. analyzed the roles of the two U2AF
subunits in vivo in the selection of alternative 3' splice
sites associated with polypyrimidine tracts of different
strengths. Their results revealed a feedback mechanism
by which RNA interference-mediated depletion of
U2AF65 triggers down regulation of U2AF35 expression.
They also showed that knockdown of each U2AF sub-
unit inhibits weak 3' splice site recognition, while over-
expression of U2AF65 alone is sufficient to activate se-
lection of this splice site [46,47]. It would be interesting
to examine if over-expression of U2AF65 alone in the
context of cancer activates splicing of weak or noncon-
sensus polypyrimidine tracts that could tip the balance
of splicing regulation in a subset of cellular transcripts
which could promote tumorigenesis.
The proteins we identified in RKO nuclear extracts
using biotin triplex DNA affinity were PSF, a 100-kDa pro-
tein that also binds to the polypyrimidine tract, and its
heterodimeric binding partner p54nrb. We speculate that
the 100- and 60-kDa proteins identified in previous stud-
ies using Southwestern blotting with HeLa nuclear
extracts [16] probed with the same purine triplex DNA
probe used in this study are indeed PSF and p54nrb, but
ββ
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Figure 6 Western blots of U2AF65, PSF, p54nrb, and beta-catenin expression in normal and tumor colorectal tissue extracts. Total
protein (25 μg) from cytoplasmic (cy) and nuclear (nu) tissue extracts obtained from six selected patients were separated using 10% SDS-PAGE
and electro-transferred to nitrocellulose membranes. Blots were incubated with the antibodies against U2AF65, PSF, p54nrb, beta-catenin, and
actin, then the appropriate secondary antibody and detected using chemiluminescence and autoradiography. Each patient’s tumor stage and
number which are also included in Figure 1, and corresponding EMSA H3 values are shown above the samples.
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double-stranded (ds)DNA, single-stranded (ss)DNA, and
RNA, and contain DNA- and RNA-binding domains. PSF
participates in constitutive pre-mRNA splicing and is a
component of later spliceosomal B and C complexes
(when U2AF65 is no longer present). PSF and p54nrb also
bind and function in nuclear retention of defective RNAs
and are involved in transcriptional regulation and the
DNA damage response [48-51]. Interestingly, PSF also
functions in DNA annealing, where PSF requires ssDNA
and dsDNA with sequence homology for their in vitro
pairing activity as well as divalent cations. PSF can pro-
mote the incorporation of ssDNA within the two sepa-
rated strands of a homologous superhelical DNA duplex
and produce a three-stranded D-loop structure, which is
required for homologous recombination. Other splicing
factors SF2/ASF and U2AF65 also caused DNA annealing
but could not form D loops [52]. PSF and p54nrb, as well
as GRSF-1, YB-1, and polypyrimidine tract-binding pro-
tein (PTB) also bind to the MYC family of internal ribo-
some entry sites (IRES) and positively regulate translation
of the Myc family of oncoproteins in vitro and in vivo
[53]. Protein array data in this study showed that expres-
sion of both PSF and p54nrb in colorectal tissue extracts
correlated significantly with c-Myc expression levels,
which is consistent with a role for PSF and p54nrb in the
regulation of c-Myc protein expression.
Researchers identified both U2AF and PSF, as well as
hnRNP C and PTB, as RNA-binding proteins that bind
to two regions 3’ of the (CUG)n repeat expansion in the
3’-UTR of the DMPK gene, where expansion of this tri-
nucleotide repeat causes the neuromuscular disorder
myotonic dystrophy [54]. Their study explored RNA-
binding proteins interacting with non-CUG regions or
higher order structures in the DMPK 3’-UTR that may
be involved in RNA-mediated pathogenesis. Their find-
ing that both U2AF and PSF can bind near this triplet
repeat sequence with the potential to form higher order
structures such as triplexes is consistent with our data
on biotin triplex DNA affinity identification of both
U2AF65 and PSF. Another group identified an RNA/
protein complex in both Drosophila and 293 cells that
consisted of expanded CAG RNA, U2AF65, and the
NXF1 nuclear export receptor, providing further evi-
dence that in other models, U2AF65 interacts with these
triplet repeat sequences [55]. We believe that the purine
triplex DNA EMSA probe can be a surrogate multiplexnucleic acid structure that acts as a “bait and hook” to
capture proteins that may be binding D-loops, R-loops,
triplexes, G-quadruplexes, or other multi-stranded struc-
tures containing Hoogsteen or reverse Hoogsteen base
pairs in vivo.
PTB also binds to polypyrimidine tracts in pre-mRNAs,
and numerous studies have shown that PTB competes
with U2AF65 for binding to these sequences [56-61].
Since PSF is a PTB-associated protein, binding competi-
tion between PSF and U2AF65 may be possible as well,
which may explain why we identified both PSF with the
biotinylated triplex DNA in RKO nuclear extracts and
U2AF65 in RKO cytoplasmic extracts. Gama-Carvalho
and colleagues performed immunoprecipitation of
U2AF65- and PTB-associated RNAs from HeLa cells fol-
lowed by microarray analysis to determine which mRNAs
are associated with these two splicing factors that can
compete for binding to polypyrimidine tracts [36]. Among
U2AF65-associated mRNAs was a predominance of tran-
scription factors and cell cycle regulators, whereas PTB-
associated transcripts were enriched in mRNAs that en-
code proteins implicated in intracellular transport, vesicle
trafficking, and apoptosis.
Related to cancer, researchers found that 2 of 14 patients
with malignant mesothelioma, a pulmonary malignancy,
had antibodies against U2AF65 using the SEREX tech-
nique (serologic identification by recombinant expression
cloning) [62]. Additionally, a patient with liver cirrhosis
that progressed to hepatocellular carcinoma had antinuc-
lear antibodies that recognized a nuclear protein putatively
identified as U2AF65 [63]. Other splicing factors, most
notably SFRS1 (ASF/SF2), are reported to be over-
expressed in colon, thyroid, kidney, lung and breast cancer
cells [64]. Other splicing factors shown to be over-
expressed in colorectal cancer cells are hnRNP-F and –K,
SPF45, and SRPK1 [64]. However, the present report is the
first to describe correlation of increased expression or
binding activity of U2AF65 in primary colorectal tumors
with tumor stage, lymph node disease, metastasis and
reduced overall survival.
Why U2AF65 is over-expressed in colorectal tumor
cells, and whether this over-expression is important to
the development and/or progression of colorectal cancer
or a passive effect of general gene deregulation are un-
known. About 75% of sporadic colorectal cancers are
characterized by a chromosomal instability (CIN) pheno-
type. The most common reported chromosomal losses
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most common gains involve 8q and 20q. The gene en-
coding U2AF65 (U2AF2) is located at c19q13.42.
Chromosomal amplifications at c19q13.42 have been
found in a rare embryonal tumor using array CGH and
FISH [65,66]. Other groups have reported amplifications
or aberrations at c19q13 in colorectal tumors, particu-
larly in liver metastases compared to primary tumors
[67], and in other solid tumors including pancreatic [68]
and ovarian [69].
Regarding genomic instability, Vasquez and colleagues
recently showed that both non-B DNA sequences and
WRN helicase deficiency induce mutations characterized
by single base changes, mostly at C-G base pairs, in an
additive but not synergistic manner [70]. Because no syn-
ergy was observed, the authors concluded that a role for
WRN in reducing mutation frequencies via a mechanism
dependent on its cellular helicase activity (for example,
of non-B DNA sequences) is unlikely. Their data do not
directly support our present hypothesis, which is similar
to their hypothesis that if one function of the WRN heli-
case were to resolve non-B (triplex and Z-DNA) struc-
tures, as observed in vitro, then mutation frequencies
may be higher in WRN-deficient cells than in WRN-wild
type cells because both the number and stability of such
structures would be greater in WRN-deficient cells.
However, they did verify that purified WRN protein was
able to unwind the third purine-rich strand of a synthetic
triplex in vitro. Although our data suggest a correlation
between expression of the WRN helicase with triplex
DNA-binding activity in both normal and tumor tissue
extracts, defining a functional role and mechanism of
non-B DNA unwinding activity by WRN helicase and
G*G multiplex binding (for example, by U2AF65) will re-
quire further study.
Beta-catenin, as a transcription factor complexed with
TCF4, is known to upregulate expression of many rele-
vant proteins in colorectal cancer, such as c-myc, cyclin
D1, LEF-1, CD44, and c-jun. Whether beta-catenin
influences the expression of U2AF65 is unknown, but a
search of transcription factor binding sites in the
U2AF65 (U2AF2) gene promoter did not indicate any
beta-catenin or TCF family transcription factor sites
among the 55 high-scoring (>85%) sites we identified
(Cold Spring Harbor Laboratory Mammalian Promoter
Database http://rulai.cshl.edu/CSHLmpd2/; Transcription
Factor Search http://www.cbrc.jp/research/db/TFSEARCH.
html). Similarly, mining through microarray expression
studies revealed no reports describing U2AF65 (U2AF2) as
a beta-catenin, TCF4, or Wnt target gene (NCBI GEO; R
Nusse Wnt/Beta catenin targets list: www.stanford.edu/
~rnusse/pathways/targets.html). The biological significance
of the correlation of U2AF65 and beta-catenin expression
in colorectal tumor tissues, such as if beta-catenin as atranscription factor affects U2AF65 expression, or if
U2AF65 as a splicing factor affects the splicing or expres-
sion of beta-catenin, remains to be determined.
Several studies have examined the interaction of beta-
catenin with splicing factors and the role of beta-catenin
in mRNA splicing. Researchers identified alternative spli-
cing of SLC39A14, a divalent cation transporter, in colo-
rectal tumors and found it to be regulated by the Wnt
pathway, probably through regulation of splicing factor
SRSF1 [71]. The beta-catenin/TCF4 pathway also modifies
alternative splicing through modulation of expression of
splicing factors SRp20 [72] and SF1 [73] and direct inter-
action with FUS/TLS (translocated in liposarcoma) and
various other RNA-binding proteins, including p54nrb
[74]. Others have shown that beta-catenin regulates mul-
tiple steps of RNA metabolism in colon cancer cells and
may coordinate RNA metabolism [75].
Authors have also reported identification of truncated
beta-catenin isoforms, mostly in colorectal cancer cells.
In primary colorectal tumors, a relatively small percent
(7 of 58 examined) contained somatic interstitial deletions
that included all or part of exon 3 of the beta-catenin gene,
and RT-PCR analysis from 3 of the 7 tumors detected tran-
scripts that lacked exon 3 and the presence of the normal
transcript [39]. Researchers also detected two novel beta-
catenin mRNA splice variants in the SW480 colon cancer
cell line and in primary colorectal tumors [38]. A truncated
beta-catenin protein of 80-kDa was also detected in three
colorectal metastases to the liver [40]. Several of these iso-
forms have truncations in the NH2-terminus of the protein
that produce deletions of key serine and threonines that
are phosphorylated by GSK-3 beta, which is important for
proteosomal degradation, which was hypothesized to
stabilize the protein and have a dominant oncogenic effect
[76]. Data from this and other studies lead us to speculate
that U2AF65 could be binding to a multi-stranded nucleic
acid structure such as R-loops, D-loops, or G-quartet
mRNA in vivo that is mimicked by the purine triplex DNA
probe in our study, and that overexpression or increased
EMSA binding activity of U2AF65 in tumor tissues could
cause deregulation of mRNA splicing and protein isoform
expression, such as beta-catenin, that could contribute to
colorectal cancer initiation and/or progression.
Conclusions
We found that increased triplex DNA-binding activity
in colorectal tumor extracts in vitro is associated with
WRN helicase expression, increased total beta-catenin
expression, lymph node disease, metastasis, and
reduced overall survival in patients with colorectal
cancer. Multifunctional splicing factor U2AF65 was
identified as the major triplex-binding protein in
human tissues and cell lines. Increased expression of
U2AF65 is also associated with expression of splicing
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increased truncation of beta-catenin in colorectal
tumors. We believe that our results contribute to and
generate interest in the growing fields of alternative
non-B DNA structures and genomic instability, aber-
rantly regulated splicing factors, mRNA splicing and
protein isoforms related to cancer both as basic re-
search objectives regarding the etiology of cancer and
cancer diversity and as novel translational research in
the search for promising prognostic, diagnostic and
targeting tools.Additional files
Additional file 1: Figure S1. Electrophoretic Mobility Shift Assay (EMSA)
of patient tissue lysates and HeLa nuclear extract with triplex and parent
duplex DNA probes. 33P-labeled purine-motif duplex or triplex DNA
(1 nM) was complexed with 5 μg protein from normal tissue cytoplasmic
(N cy), normal nuclear (N nu), tumor tissue cytoplasmic (T cy) or tumor
nuclear (T nu) extracts of colorectal cancer patients. 1.25 μg HeLa nuclear
extract (H) was used as a control in lanes 6 and 12. Purine triplex probe
alone is in lane 1 and duplex probe alone is in lane 7. Figure S2a.
Electrophoretic Mobility Shift Assay (EMSA) of Cytoplasmic and Nuclear
Extracts from Eight Colorectal Cancer Cell Lines with Purine triplex DNA.
33P-labeled purine-motif triplex DNA (1 nM) was complexed with 1.25 μg
total protein from cytoplasmic (cy) or nuclear (nuc) extracts from eight
colorectal cancer cell lines. 1.25 μg HeLa cytoplasmic and nuclear extracts
were used as positive (+) controls. Each reaction also contained 2 μg
poly (dI-dC) carrier DNA. The purine triplex DNA probe alone is shown in
lane 1. Figure S2b. Western blots showing expression of three candidate
triplex DNA-binding proteins in eight colorectal cancer cell lines. Total
protein (25 μg) from cytoplasmic (cy) and nuclear (nu) extracts from
eight colorectal cancer cell lines were separated using 10% SDS-PAGE
and electro-transferred to nitrocellulose membranes. Blots were
incubated with the antibodies against PSF, U2AF65, p54nrb, beta-catenin,
and actin, then the appropriate secondary antibody and detected using
chemiluminescence and autoradiography. Figure S3. Lack of a super-
shifted H3 band in RKO nuclear extract by super-shift EMSA with
antibodies against PSF and p54nrb. 33P-labeled triplex DNA (1 nM) was
complexed with 1.5 μg total protein from RKO nuclear extracts
(lanes 2-9). Lane 1, triplex DNA probe alone; Lane 2, no antibody; lane 3,
400 ng anti-U2AF65 antibody MC3; lane 4, 1000 ng
anti-U2AF65 antibody MC3; lane 5, 400 ng anti-PSF antibody; lane 6 1000
ng anti-PSF antibody; lane 7, 400 ng anti-p54nrb antibody; lane 8, 1000
ng anti-p54nrb antibody; lane 9, mouse IgG antibody (negative control).
Each reaction also contained 2 μg poly (dI-dC) carrier DNA. Figure S4.
Quantitation of Protein Expression of PSF, U2AF65, p54nrb, and beta-
catenin obtained from six colorectal cancer patients’ tissue extracts.
Autoradiographs from Western blots in Figure 6 were scanned, and
protein expression bands were quantitated using NIH Image J. Protein
expression was normalized by dividing by the samples’ corresponding
actin value and graphed using Graph Pad. Figure S5. Beta-catenin
Expression by Tumor type and Stage. Western blots using an
anti-beta-catenin antibody to examine expression in patient extracts were
described for Figure 6. Beta-catenin expression values were normalized
by dividing the actin expression value in each extract, and plotted
according to colon or rectum tumor stage using the R program. N cyto,
cytoplasmic normal tissue extracts; N nuc, nuclear normal tissue extracts;
T cyto, cytoplasmic tumor tissue extracts; T nuc, nuclear tumor tissue
extracts.
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p values.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LDN, HM, MWVD and HA designed the study; CB, DB, PK, and GM performed
all statistical analysis and collected patient clinical data; LDN and HM
performed all experiments; UK supervised reverse phase protein array
experiments; LDN, DPH, MWVD and HA wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
We thank Mohammed Abba, Irfan Asangani, Nitin Patil, Christian Schmidt,
and Frederick Wenz for insightful discussions and assistance. We also thank
Donald Norwood for critical reading of the manuscript.
LDN is supported by a Guest Scientist Scholarship from the German Cancer
Research Center (DKFZ) and the National Cancer Institute (NCI;
1RO1CA149501-01A1). CB is supported by the network SB-Cancer in the
Helmholtz Alliance on Systems Biology, Heidelberg Germany. HM is
supported by the German Federal Ministry of Education and Science in the
framework of the program for medical genome research (01GS0890 and
01GS0864). DB is supported by the Department of Anesthesiology and
Intensive Care Medicine, Medical Faculty Mannheim, University of
Heidelberg, Mannheim Germany.
PK is supported by Experimental Surgery, Medical Faculty Mannheim,
University of Heidelberg, Mannheim Germany. GM is supported by the
Stiftung fur Krebs- und Scharlachforschung Mannheim, University of
Heidelberg, Mannheim Germany and Wilhelm Sander Foundation, Munich,
Germany. UK is supported by the German Federal Ministry of Education and
Science in the framework of the program for medical genome research
(01GS0890 and 01GS0864), Heidelberg. DPH is supported by the National
Cancer Institute (NCI; 1RO1CA149501-01A1).
MWVD is supported by the North Carolina Biotechnology Center. HA is
supported by Alfried Krupp von Bohlen and Halbach Foundation (Award for
Young Full Professors), Essen, Hella-Bühler-Foundation, Heidelberg, Dr. Ingrid
zu Solms Foundation, Frankfurt/Main, the Hector Foundation, Weinheim,
Germany, the FRONTIER Excellence Initiative of the University of Heidelberg,
the BMBF, Bonn, Germany, the Walter Schulz Foundation, Munich, Germany,
the German-Israeli Project Cooperation, DKFZ Heidelberg, and the Deutsche
Krebshilfe, Germany. Wilhelm Sander Foundation, Munich, Germany, and the
DKFZ-MOST German Israel Program.
Author details
1Dept. of Pediatrics, The University of Texas M.D. Anderson Cancer Center,
Houston, TX 77030, USA. 2Molecular Genome Analysis, German Cancer
Research Center, Heidelberg, Germany. 3Dept. of Anesthesiology and
Intensive Care Medicine, Medical Faculty Mannheim, University of
Heidelberg, Heidelberg, Germany. 4Experimental Surgery, Medical Faculty
Mannheim, University of Heidelberg, Mannheim, Germany. 5Dept of
Chemistry and Physics, Western Carolina University, Cullowhee, NC 28723,
USA. 6Molecular Oncology of Solid Tumors, German Cancer Research Center,
Heidelberg, Germany.
Received: 28 October 2011 Accepted: 26 March 2012
Published: 8 June 2012
References
1. Frank-Kamenetskii MD, Mirkin SM: Triplex DNA structures. Annu Rev
Biochem 1995, 64:65–95.
2. Patel DJ, Phan AT, Kuryavyi V: Human telomere, oncogenic promoter and
5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for
cancer therapeutics. Nucleic Acids Res 2007, 35:7429–7455.
3. Belotserkovskii BP, De Silva E, Tornaletti S, Wang G, Vasquez KM, Hanawalt
PC: A triplex-forming sequence from the human c-MYC promoter
interferes with DNA transcription. J Biol Chem 2007, 282:32433–32441.
Nelson et al. Molecular Cancer 2012, 11:38 Page 16 of 17
http://www.molecular-cancer.com/content/11/1/384. Nikolova EN, Kim E, Wise AA, O'Brien PJ, Andricioaei I, Al-Hashimi HM:
Transient Hoogsteen base pairs in canonical duplex DNA. Nature 2011,
470:498–502.
5. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell
2011, 144:646–674.
6. Bacolla A, Wells RD: Non-B DNA conformations as determinants of
mutagenesis and human disease. Mol Carcinog 2009, 48:273–285.
7. Mirkin SM: Expandable DNA repeats and human disease. Nature 2007,
447:932–940.
8. Napierala M, Bacolla A, Wells RD: Increased negative superhelical density
in vivo enhances the genetic instability of triplet repeat sequences. J Biol
Chem 2005, 280:37366–37376.
9. Zhao J, Bacolla A, Wang G, Vasquez KM: Non-B DNA structure-induced
genetic instability and evolution. Cell Mol Life Sci 2010, 67:43–62.
10. Jain A, Wang G, Vasquez KM: DNA triple helices: biological consequences
and therapeutic potential. Biochimie 2008, 90:1117–1130.
11. Bacolla A, Collins JR, Gold B, Chuzhanova N, Yi M, Stephens RM, Stefanov S,
Olsh A, Jakupciak JP, Dean M, et al: Long homopurine*homopyrimidine
sequences are characteristic of genes expressed in brain and the
pseudoautosomal region. Nucleic Acids Res 2006, 34:2663–2675.
12. Joos S, Haluska FG, Falk MH, Henglein B, Hameister H, Croce CM, Bornkamm
GW: Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations
far upstream of c-myc. Cancer Res 1992, 52:6547–6552.
13. Wang G, Vasquez KM: Naturally occurring H-DNA-forming sequences are
mutagenic in mammalian cells. Proc Natl Acad Sci U S A 2004,
101:13448–13453.
14. Cer RZ, Bruce KH, Mudunuri US, Yi M, Volfovsky N, Luke BT, Bacolla A,
Collins JR, Stephens RM: Non-B DB: a database of predicted non-B DNA-
forming motifs in mammalian genomes. Nucleic Acids Res 2011,
39:D383–D391.
15. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB: Fragile X
mental retardation protein targets G quartet mRNAs important for
neuronal function. Cell 2001, 107:489–499.
16. Musso M, Nelson LD, Van Dyke MW: Characterization of purine-motif
triplex DNA-binding proteins in HeLa extracts. Biochemistry 1998,
37:3086–3095.
17. Nelson LD, Musso M, Van Dyke MW: The Yeast STM1 Gene Encodes a
Purine Motif Triple Helical DNA-binding Protein. J Biol Chem 2000,
275:5573–5581.
18. Van Dyke MW, Nelson LD, Weilbaecher RG, Mehta DV: Stm1p, a G4
Quadruplex and Purine Motif Triplex Nucleic Acid-binding Protein,
Interacts with Ribosomes and Subtelomeric Y' DNA in Saccharomyces
cerevisiae. J Biol Chem 2004, 279:24323–24333.
19. Frantz JD, Gilbert W: A yeast gene product, G4p2, with a specific affinity
for quadruplex nucleic acids. J Biol Chem 1995, 270:9413–9419.
20. Ozgenc A, Loeb LA: Current advances in unraveling the function of the
Werner syndrome protein. Mutat Res 2005, 577:237–251.
21. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H:
Colorectal cancer and polymorphisms in DNA repair genes WRN, RMI1
and BLM. Carcinogenesis 2010, 31:442–445.
22. Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M,
Fuchs CS, Ogino S: WRN promoter methylation possibly connects
mucinous differentiation, microsatellite instability and CpG island
methylator phenotype in colorectal cancer. Mod Pathol 2008, 21:150–158.
23. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D: Genetic
prognostic and predictive markers in colorectal cancer. Nat Rev Cancer
2009, 9:489–499.
24. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, Protopopov A,
Ivanova E, Brennan C, Montgomery K, et al: Common and distinct genomic
events in sporadic colorectal cancer and diverse cancer types. Cancer Res
2007, 67:10736–10743.
25. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM,
Barber T, Ptak J, et al: The genomic landscapes of human breast and
colorectal cancers. Science 2007, 318:1108–1113.
26. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of
human breast and colorectal cancers. Science 2006, 314:268–274.
27. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S,
Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulatestumor suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene 2008, 27:2128–2136.
28. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of
octamer binding proteins with 'mini-extracts', prepared from a small
number of cells. Nucleic Acids Res 1989, 17:6419.
29. Ausubel FM: Current protocols in molecular biology. Brooklyn, N.Y. Media, Pa:
Greene Pub. Associates. J. Wiley, order fulfillment; 1987.
30. Mannsperger HA, Uhlmann S, Schmidt C, Wiemann S, Sahin O, Korf U: RNAi-
based validation of antibodies for reverse phase protein arrays. Proteome
Sci 2010, 8:69.
31. Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U:
Infrared-based protein detection arrays for quantitative proteomics.
Proteomics 2007, 7:558–564.
32. Mannsperger HA, Gade S, Henjes F, Beissbarth T, Korf U: RPPanalyzer: Analysis
of reverse-phase protein array data. Bioinformatics 2010, 26:2202–2203.
33. Straub T, Grue P, Uhse A, Lisby M, Knudsen BR, Tange TO, Westergaard O,
Boege F: The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I
activity by a direct interaction. J Biol Chem 1998, 273:26261–26264.
34. Shi Y, Di Giammartino DC, Taylor D, Sarkeshik A, Rice WJ, Yates JR, Frank J,
Manley JL: Molecular architecture of the human pre-mRNA 3' processing
complex. Mol Cell 2009, 33:365–376.
35. Gama-Carvalho M, Carvalho MP, Kehlenbach A, Valcarcel J, Carmo-Fonseca
M: Nucleocytoplasmic Shuttling of Heterodimeric Splicing Factor U2AF.
J Biol Chem 2001, 276:13104–13112.
36. Gama-Carvalho M, Barbosa-Morais NL, Brodsky AS, Silver PA, Carmo-Fonseca
M: Genome-wide identification of functionally distinct subsets of cellular
mRNAs associated with two nucleocytoplasmic-shuttling mammalian
splicing factors. Genome Biol 2006, 7:R113.
37. Gama-Carvalho M, Krauss RD, Chiang L, Valcarcel J, Green MR, Carmo-
Fonseca M: Targeting of U2AF65 to Sites of Active Splicing in the
Nucleus. J Cell Biol 1997, 137:975–987.
38. Pospisil H, Herrmann A, Butherus K, Pirson S, Reich JG, Kemmner W:
Verification of predicted alternatively spliced Wnt genes reveals two
new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression
during tumour progression. BMC Genomics 2006, 7:148.
39. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T,
Ishiguro S, Nakamura Y, Miyoshi Y: Activation of the beta-catenin gene by
interstitial deletions involving exon 3 in primary colorectal carcinomas
without adenomatous polyposis coli mutations. Cancer Res 1998,
58:1021–1026.
40. Hugh TJ, Dillon SA, O'Dowd G, Getty B, Pignatelli M, Poston GJ, Kinsella AR:
beta-catenin expression in primary and metastatic colorectal carcinoma.
Int J Cancer 1999, 82:504–511.
41. Zamore PD, Green MR: Biochemical characterization of U2 snRNP auxiliary
factor: an essential pre-mRNA splicing factor with a novel intranuclear
distribution. EMBO J 1991, 10:207–214.
42. Ruskin B, Zamore PD, Green MR: A factor, U2AF, is required for U2 snRNP
binding and splicing complex assembly. Cell 1988, 52:207–219.
43. Gaur RK, Valcarcel J, Green MR: Sequential recognition of the pre-mRNA
branch point by U2AF65 and a novel spliceosome-associated 28-kDa
protein. RNA 1995, 1:407–417.
44. Sridharan V, Heimiller J, Singh R: Genomic mRNA profiling reveals
compensatory mechanisms for the requirement of the essential splicing
factor U2AF. Mol Cell Biol 2011, 31:652–661.
45. Zolotukhin AS, Tan W, Bear J, Smulevitch S, Felber BK: U2AF participates in
the binding of TAP (NXF1) to mRNA. J Biol Chem 2002, 277:3935–3942.
46. Pacheco TR, Moita LF, Gomes AQ, Hacohen N, Carmo-Fonseca M: RNA
interference knockdown of hU2AF35 impairs cell cycle progression and
modulates alternative splicing of Cdc25 transcripts. Mol Biol Cell 2006,
17:4187–4199.
47. Pacheco TR, Coelho MB, Desterro JMP, Mollet I, Carmo-Fonseca M: In Vivo
Requirement of the Small Subunit of U2AF for Recognition of a Weak 3'
Splice Site. Mol Cell Biol 2006, 26:8183–8190.
48. Shav-Tal Y, Zipori D: PSF and p54(nrb)/NonO–multi-functional nuclear
proteins. FEBS Lett 2002, 531:109–114.
49. Salton M, Lerenthal Y, Wang SY, Chen DJ, Shiloh Y: Involvement of
matrin 3 and SFPQ/NONO in the DNA damage response. Cell Cycle 2010,
9:1568–1576.
50. Li S, Kuhne WW, Kulharya A, Hudson FZ, Ha K, Cao Z, Dynan WS:
Involvement of p54(nrb), a PSF partner protein, in DNA double-strand
break repair and radioresistance. Nucleic Acids Res 2009, 37:6746–6753.
Nelson et al. Molecular Cancer 2012, 11:38 Page 17 of 17
http://www.molecular-cancer.com/content/11/1/3851. Bladen CL, Udayakumar D, Takeda Y, Dynan WS: Identification of the
polypyrimidine tract binding protein-associated splicing factor.p54(nrb)
complex as a candidate DNA double-strand break rejoining factor. J Biol
Chem 2005, 280:5205–5210.
52. Akhmedov AT, Lopez BS: Human 100-kDa homologous DNA-pairing
protein is the splicing factor PSF and promotes DNA strand invasion.
Nucleic Acids Res 2000, 28:3022–3030.
53. Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de Moor CH,
Lilley KS, Bushell M, Willis AE: Identification of internal ribosome entry
segment (IRES)-trans-acting factors for the Myc family of IRESs. Mol Cell
Biol 2008, 28:40–49.
54. Tiscornia G, Mahadevan MS: Myotonic dystrophy: the role of the CUG
triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic
DMPK mRNA isoform ratios. Mol Cell 2000, 5:959–967.
55. Tsoi H, Lau CK, Lau KF, Chan HY: Perturbation of U2AF65/NXF1-mediated
RNA nuclear export enhances RNA toxicity in polyQ diseases. Hum Mol
Genet 2011, 20:3787–3797.
56. Castelo-Branco P, Furger A, Wollerton M, Smith C, Moreira A, Proudfoot N:
Polypyrimidine tract binding protein modulates efficiency of
polyadenylation. Mol Cell Biol 2004, 24:4174–4183.
57. Izquierdo JM, Majos N, Bonnal S, Martinez C, Castelo R, Guigo R, Bilbao D,
Valcarcel J: Regulation of Fas alternative splicing by antagonistic effects
of TIA-1 and PTB on exon definition. Mol Cell 2005, 19:475–484.
58. Sharma S, Falick AM, Black DL: Polypyrimidine tract binding protein blocks
the 5' splice site-dependent assembly of U2AF and the prespliceosomal
E complex. Mol Cell 2005, 19:485–496.
59. Sauliere J, Sureau A, Expert-Bezancon A, Marie J: The polypyrimidine tract
binding protein (PTB) represses splicing of exon 6B from the beta-
tropomyosin pre-mRNA by directly interfering with the binding of the
U2AF65 subunit. Mol Cell Biol 2006, 26:8755–8769.
60. Marinescu V, Loomis PA, Ehmann S, Beales M, Potashkin JA: Regulation of
retention of FosB intron 4 by PTB. PLoS One 2007, 2:e828.
61. Cosme RS, Yamamura Y, Tang Q: Roles of polypyrimidine tract binding
proteins in major immediate-early gene expression and viral replication
of human cytomegalovirus. J Virol 2009, 83:2839–2850.
62. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA:
Serologic responses in patients with malignant mesothelioma: evidence
for both public and private specificities. Am J Respir Cell Mol Biol 2000,
22:550–556.
63. Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM: Novel nuclear autoantigen
with splicing factor motifs identified with antibody from hepatocellular
carcinoma. J Clin Invest 1993, 92:2419–2426.
64. Grosso AR, Martins S, Carmo-Fonseca M: The emerging role of splicing
factors in cancer. EMBO Rep 2008, 9:1087–1093.
65. Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, Tobias V,
Buccoliero AM, Sardi I, Gardiman MP, et al: Focal genomic amplification at
19q13.42 comprises a powerful diagnostic marker for embryonal tumors
with ependymoblastic rosettes. Acta Neuropathol 2010, 120:253–260.
66. Pfister S, Remke M, Castoldi M, Bai AH, Muckenthaler MU, Kulozik A, von
Deimling A, Pscherer A, Lichter P, Korshunov A: Novel genomic
amplification targeting the microRNA cluster at 19q13.42 in a pediatric
embryonal tumor with abundant neuropil and true rosettes. Acta
Neuropathol 2009, 117:457–464.
67. Sayagues JM, Abad MM, Melchor HB, Gutierrez ML, Gonzalez-Gonzalez M,
Jensen E, Bengoechea O, Fonseca E, Orfao A, Munoz-Bellvis L:
Intratumoural cytogenetic heterogeneity of sporadic colorectal
carcinomas suggests several pathways to liver metastasis. J Pathol 2010,
221:308–319.
68. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter
G, Kallioniemi A: 19q13 amplification is associated with high grade and stage
in pancreatic cancer. Genes Chromosomes Cancer 2010, 49:569–575.
69. Bayani J, Marrano P, Graham C, Zheng Y, Li L, Katsaros D, Lassus H, Butzow
R, Squire JA, Diamandis EP: Genomic instability and copy-number
heterogeneity of chromosome 19q, including the kallikrein locus, in
ovarian carcinomas. Mol Oncol 2011, 5:48–60.
70. Bacolla A, Wang G, Jain A, Chuzhanova NA, Cer RZ, Collins JR, Cooper DN,
Bohr VA, Vasquez KM: Non-B DNA-forming sequences and WRN
deficiency independently increase the frequency of base substitution in
human cells. J Biol Chem 2011, 286:10017–10026.
71. Thorsen K, Mansilla F, Schepeler T, Oster B, Rasmussen MH, Dyrskjot L,
Karni R, Akerman M, Krainer AR, Laurberg S, et al: Alternative splicing ofSLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell
Proteomics 2011, 10:M110 002998.
72. Goncalves V, Matos P, Jordan P: The beta-catenin/TCF4 pathway modifies
alternative splicing through modulation of SRp20 expression. RNA 2008,
14:2538–2549.
73. Shitashige M, Naishiro Y, Idogawa M, Honda K, Ono M, Hirohashi S,
Yamada T: Involvement of splicing factor-1 in beta-catenin/T-cell factor-
4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology
2007, 132:1039–1054.
74. Sato S, Idogawa M, Honda K, Fujii G, Kawashima H, Takekuma K, Hoshika A,
Hirohashi S, Yamada T: beta-catenin interacts with the FUS proto-
oncogene product and regulates pre-mRNA splicing. Gastroenterology
2005, 129:1225–1236.
75. Lee HK, Kwak HY, Hur J, Kim IA, Yang JS, Park MW, Yu J, Jeong S: beta-
catenin regulates multiple steps of RNA metabolism as revealed by the
RNA aptamer in colon cancer cells. Cancer Res 2007, 67:9315–9321.
76. Wagenaar RA, Crawford HC, Matrisian LM: Stabilized beta-catenin
immortalizes colonic epithelial cells. Cancer Res 2001, 61:2097–2104.
doi:10.1186/1476-4598-11-38
Cite this article as: Nelson et al.: Triplex DNA-binding proteins are
associated with clinical outcomes revealed by proteomic measurements
in patients with colorectal cancer. Molecular Cancer 2012 11:38.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
